[{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"T Cell Therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Thomas Jefferson University","highestDevelopmentStatusID":"5","companyTruncated":"Tevogen Bio \/ Thomas Jefferson University"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Biocentriq","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"Purified Cytotoxic CD8+ T Lymphocytes","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Tevogen Bio \/ Tevogen Bio","highestDevelopmentStatusID":"5","companyTruncated":"Tevogen Bio \/ Tevogen Bio"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"TVGN-489","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"T Cell Therapy","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"HMP Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"TVGN-489","moa":"CD8+ T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tevogen Bio \/ HMP Partners","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ HMP Partners"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"T Cell Therapies","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"TVGN-489","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Semper Paratus Acquisition Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Merger","leadProduct":"TVGN-489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Semper Paratus Acquisition Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Semper Paratus Acquisition Corporation"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"TVGN 489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"TVGN-489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"TVGN 489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Tevogen Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"TVGN 489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"TVGN 489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"TVGN 920","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tevogen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Microsoft","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"TVGN 920","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Microsoft","highestDevelopmentStatusID":"4","companyTruncated":"Tevogen Bio \/ Microsoft"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"Microsoft","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Tevogen Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Tevogen Bio \/ Microsoft","highestDevelopmentStatusID":"3","companyTruncated":"Tevogen Bio \/ Microsoft"},{"orgOrder":0,"company":"Tevogen Bio","sponsor":"KRHP LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Financing","leadProduct":"TVGN 489","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Tevogen Bio","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Tevogen Bio \/ KRHP LLC","highestDevelopmentStatusID":"6","companyTruncated":"Tevogen Bio \/ KRHP LLC"}]
Find Clinical Drug Pipeline Developments & Deals by Tevogen Bio
Details :
The grant funding will further Tevogen Bio’s mission to develop T cell therapeutics, including TVGN 489, for treatment of cancers and viral infections.
Details :
Tevogen has collaborates with Microsoft to develop new algorithms for decoding interactions between HLA and T cells, aiming to accelerate target identification and strengthen Tevogen Bio’s pipeline.
Details :
Using Microsoft’s suite of advanced tools, Tevogen Bio is proactively investigating potential treatments for HPV to create a portfolio of oncology products including TVGN 920.
Details :
TVGN 920, will be manufactured utilizing Tevogen’s proprietary ExacTcell™ technology, in which genetically unmodified, allogeneic cytotoxic CD8+ CTLs with precise targets HPV infection.
Details :
The proceeds will support research and development, particularly focusing on TVGN 489 the company’s initial product from its ExacTcell™ technology platform, for the treatment of COVID-19.
Details :
TVGN 489 contains Cytotoxic T lymphocytes that recognize multiple SARS-CoV-2 proteins, or peptides. TVGN 489’s peptide targets have been preserved in all previously studied COVID strains
Details :
This financing supports Tevogen Bio’s pursuit of expanding research and development efforts with a focus on continued clinical development of the company’s initial product, TVGN 489 for covid 19.
Details :
TVGN-489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product, which is being evaluated for the treatment of High-Risk JN.1 Variant Covid19 Infection.
Details :
TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome. It is being evaluated for the treatment of long covid.
Details :
The combined company will focus on the development of CD8+ cytotoxic T lymphocytes, including TVGN-489, for the treatment of infectious diseases, cancers, and neurological disorders.
Reset All
